Price
$300.70
Decreased by -1.32%
Dollar volume (20D)
705.20 M
ADR%
1.71
Earnings report date
Aug 1, 2024
Shares float
534.88 M
Shares short
10.25 M [1.92%]
Shares outstanding
536.44 M
Market cap
163.46 B
Beta
0.60
Price/earnings
43.47
20D range
295.49 319.17
50D range
258.84 320.32
200D range
242.81 324.86

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.

The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels.

The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development.

Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
May 14, 24 3.96
Decreased by -0.50%
3.87
Increased by +2.33%
Mar 5, 24 4.40
Increased by +7.58%
4.30
Increased by +2.33%
Oct 31, 23 4.96
Increased by +5.53%
4.67
Increased by +6.21%
Aug 3, 23 5.00
Increased by +7.53%
4.49
Increased by +11.36%
Apr 27, 23 3.98
Decreased by -6.35%
3.85
Increased by +3.38%
Jan 31, 23 4.09
Decreased by -6.19%
4.10
Decreased by -0.24%
Nov 3, 22 4.70
Increased by +0.64%
4.44
Increased by +5.86%
Aug 4, 22 4.65
Increased by +6.16%
4.40
Increased by +5.68%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 24 7.40 B
Increased by +21.15%
-113.00 M
Decreased by -103.98%
Decreased by -1.53%
Decreased by -103.28%
Dec 31, 23 8.20 B
Increased by +19.84%
767.00 M
Decreased by -52.54%
Increased by +9.36%
Decreased by -60.40%
Sep 30, 23 6.90 B
Increased by +3.77%
1.73 B
Decreased by -19.27%
Increased by +25.06%
Decreased by -22.21%
Jun 30, 23 6.99 B
Increased by +5.94%
1.38 B
Increased by +4.71%
Increased by +19.74%
Decreased by -1.17%
Mar 31, 23 6.11 B
Decreased by -2.13%
2.84 B
Increased by +92.48%
Increased by +46.54%
Increased by +96.67%
Dec 31, 22 6.84 B
Decreased by -0.10%
1.62 B
Decreased by -14.90%
Increased by +23.63%
Decreased by -14.82%
Sep 30, 22 6.65 B
Decreased by -0.81%
2.14 B
Increased by +13.75%
Increased by +32.22%
Increased by +14.67%
Jun 30, 22 6.59 B
Increased by +1.04%
1.32 B
Increased by +183.84%
Increased by +19.97%
Increased by +180.91%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY